NHS declines to approve Alzheimer’s drug donanemab over cost and effectiveness concerns

The UK’s National Institute for Health and Care Excellence (Nice) has declined to approve the Alzheimer’s drug donanemab for NHS use, despite its approval by the Medicines and Healthcare Regulatory Authority. Nice cited concerns over cost-effectiveness and modest benefits. Donanemab, which targets amyloid plaques in the brain, is not a cure and shows limited improvement in symptoms. Clinical trials indicated only a small difference in cognitive decline compared to a placebo, raising questions about its overall effectiveness. Additionally, donanemab has significant side effects, including brain swelling and bleeding. Nice emphasized the need for careful consideration of treatment options, prioritizing social care and support for families affected by Alzheimer’s.